Arrow Left Research

Translational Pathways

Chair: University of Nottingham

This cluster ensured that findings from the RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System) Clinical Disorders and Technical Platforms clusters were translated efficiently and effectively into real-world clinical applications. We aimed to have workable clinical devices entering health services by 2020.  To achieve this, we needed to understand and learn from the needs of patients, clinical services and regulators.

Patient Involvement (Work Package 2)

We worked with patient stakeholders to understand issues such as privacy, usability, and acceptability of remote measurement technologies. We also worked to identify clinical endpoints which are most relevant to patients, and identify facilitators and challenges for engagement and adherence that were further tested in this project.

Clinical Pathways (Work Package 9)

We explored how remote measurement technology (RMT) could be incorporated into clinical pathways in different European healthcare systems, through literature reviews, surveys, and interviews with healthcare professionals. We developed and evaluated a set of use cases with healthcare professionals across Europe to enable prioritisation of future research approaches on RMT. We also explored potential benefits of RMT to pharmaceutical organisations and examined potential pathways to reimbursement. The findings were brought together to establish a value proposition for RMT in the three conditions.

Regulation (Work Package 10)

We worked with EU medical device and product regulators to understand their requirements in this field. We provided a structure to ensure that the regulatory learning during the project was collected and integrated to ensure its maximum applicability, acceptability and adoption. This work package focused on providing a framework for the classification of remote measurement technologies as medical devices or otherwise, and also aimed to identify what kind of information is needed for regulatory approval. 

Share this page…